DOCSLIB.ORG

An Introduction to the Drug Development Unit of the Royal Marsden NHS Foundation Trust & the Institute of Cancer Research, UK

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Introduction to the Drug Development Unit of the Royal Marsden NHS Foundation Trust & the Institute of Cancer Research, UK An introduction to the Drug Development Unit of The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, UK Acknowledgements: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support is also provided by the Experimental Cancer Medicine Centre (programme grant) (to The ICR) and the National Institute for Health Research Biomedical Research Centre (jointly awarded to the RM NHS Foundation Trust and The ICR. Celebrating 10 Years of the Drug Development Unit The Drug Development Unit (DDU) was founded in February 2005 as a dedicated Phase I oncology clinical trial centre, designed and established through collaboration between Scientists & Clinicians at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. DDU has grown from strength to strength since its inception with the support of researchers across multidisciplinary teams; our funders; and most important of all, our patients who trusted in the Unit. DDU is one of the leading clinical centres in the world providing novel drugs to over 300 patients within phase I trials each year & conducting about 45 Phase I clinical trials at any given DDU 2005 time. The success of DDU is built on its collaborative partnership between laboratory and clinical t eams, a conduit that is critical to the modern drug development process. Aims and Timeline of DDU Structure and Work of the Unit during the Principles Achievements last 10 years 2005 Number of trials enrolling patients The aim of the Drug The Drug Development Unit opens Development Unit is to with Prof Stan Kaye as the Director of DDU per year 50 seamlessly integrate 2005 45 2005 A number of drugs designed and developed in ICR Total members of staff: 40 were moved to Phase I trials in DDU. ICR 40 preclinical drug discovery, 3 Consultants; 7 Clinical Staff ; developed on average two drug development 35 1 Clinical Trial Manager; 20 Research Nurses; candidates per year. 30 proof-of-principle phase I 5 Trial management Staff; 4 Support Staff 25 trials and tumour-specific 20 2006 15 In conjunction with The Royal Marsden NHS evaluation of novel agents. 10 Foundation Trust, the ICR tested a promising new Number ofNumber trials 5 prostate cancer drug called Abiraterone, which it discovered and developed. 0 Priorities of DDU are: 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Figure 1 To maintain very high 2010 2010 Total members of staff: 77 A Phase III trial reported that abiraterone could Graph showing the number of trials facilitated by the Drug Development unit from 2005 to levels of patient safety at 4 Consultants; 12 Clinical Fellows; extend survival from 10.9 months to 14.8 months 2015. With 27 trials in 2005 and 47 in 2015, The Drug Development Unit has seen a steady 20 Research Nurses; 1 Radiology Fellow; compared to a placebo, in men with late stage increase in the number of open trials over the past 10 years. The types of drugs used in the all times. 1 Clinical Trial Manager; 2 Regulatory Officer; prostate cancer. trials have also changed. In 2005, there was a focus on single agent drugs, specifically 1 Compliance Manager; inhibitors. However, recently, there has been an increase in the number of trials using To take forward rationally 19 Trial Management Staff; combination therapies. There has also been a rise in the variety of trials undertaken by DDU; 14 Support Staff; 1 Laboratory Staff; 2011 these include the use of immunotherapies, monoclonal antibodies, and alkylating agents. designed drugs 2 Pharmacy Staff Rated “Outstanding” by the Experimental Cancer Medicine Centre Network discovered specifically at The FDA approved Abiraterone for sale under the trade name Zytiga. the ICR. Prof. Johann de Bono received prestigious Number of patients enrolled ESMO Award. To explore first-in-man per year 2012 300 studies and first-in-man 2012 Recipient of the Team Science Award from the 250 Appointment of Prof Johann de Bono American Association for Cancer Research combinations of drugs. as the Director of DDU (AACR). This was the first time that the award has 200 To develop drugs that are ever been won by a team from outside the USA. The AACR said its decision was based on “the 150 2013 tremendous impact this team has had in preclinical Establishment of the Investigator Initiated stratified and personalised and clinical studies of cancer therapeutics.” Trials team (IIT) to sponsor, design and 100 to patients in need. execute biomarker driven and stratified academic studies. 2013 50 To test novel therapies Received CRUK translational Research Award at ofNumber patients 0 Total members of IIT staff: 3 the NCRI conference. 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 which would otherwise not 1 Head of IIT; 2 Trial Management Staff Figure 2 transition to next stages. 2014 Graph showing the number of patients recruited onto trials facilitated by the Drug DDU Fellows received Merit Awards at AACR, Development Unit from 2005 to 2015. The sharp increase seen in 2009 and 2010 ASCO and ESMO Conferences. corresponds to the large number of Merck trials run by the unit. Merck trials are reputed to 2015 Study setup of ComPAKT, by IIT, is the fastest be particularly fast recruiting. Total members of staff: 96 study to be set up as part of the alliance. 5 Consultants; 1 Radiology Consultant; 12 Clinical Fellows; 1 Radiology Fellow; 27 Research Nurses; Snapshots of primary tumour sites 1 Head of Operations; 1 Administrator; 2015 2 Regulatory Officers; BBC’s Panorama team was given unprecedented treated in 2005 and 2015 1 Compliance Manager; 1 Finance access to trials and ongoing research at the ICR 60 Coordinator; 19 Trial Management Staff; and The Royal Marsden. The resulting episode, 14 Support Staff; 3 Pharmacy Staff; Can You Cure My Cancer?, was aired on BBC 1. 50 2 Laboratory Staff. 40 1 Head of IIT; 5 IIT Trial Management Staff. 2016 30 Patient Satisfaction Survey gave Oak ward and 2017 Oak Day Unit a 5 star score rating, with 100% of all 20 Plans are being considered to relocate the patients reviewed stating that they were likely to 10 Unit to a new building to support the recommend us to family and friends. development of DDU’s infrastructure. Number ofNumber patients 0 DDU 2016 2005 2015 Figure 3 Graph showing the primary tumour sites of patients treated by DDU, comparing the metrics between 2005 and 2015. Acknowledgements: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support is also provided by the Experimental Cancer Medicine Centre (programme grant to the ICR) and the National Institute for Health Research Biomedical Research Centre (jointly awarded to The Royal Marsden NHS Foundation Trust and the ICR). Celebrating 10 Years of the Drug Development Unit The Drug Development Unit is committed to the early and optimal development of anti-cancer drugs which are novel and rationally designed to maximise the likelihood of patient benefit by strategically targeting molecular abnormalities and key cellular switches hijacked by cancer cells. Phase-1 trials of ICR Drugs Drug Mechanics Sponsor Fast tracking the Abiraterone CYP17 inhibitor Janssen Biotech development of anti- GDC-0941 PI3K inhibitor Genentech-Roche cancer drugs designed and synthesised at ICR AUY922 HSP90 inhibitor Novartis DRUG to maximise their potential CHR3996 HDAC inhibitor Chroma Therapeutics DEVELOPMENT towards the care of cancer AT13148 ROCK inhibitor CRUK UNIT patients. AZD5363 AKT inhibitor AstraZeneca Onx0801 α-Folate Receptor Onyx Pharmaceuticals BAL3833 PANRaf inhibitor Basilea Pharmaceutica CCT245737 CHK1 inhibitor CRUK Conducting early-phase clinical trials focused on translating the Licenced Drugs understanding of cancer biology to improve patient Drug License Sponsor care as rapidly as Abiraterone Zytega® Janssen Biotech possible. Olaparib Lynparza® AstraZeneca RAD001 Afinitor® Novartis Effective Collaboration and Strategic Team PDX101 Belinostat® Novartis Science approach to enhance outcome of Conducting biomarker- drug development driven early clinical Number Of Drugs transitioned to next stages process. trials focused on defining Stages Number Common Disease Types tolerability, proof of of Drugs mechanism and proof of Phase II Lung, Liver, Breast, Prostate, concept. 15 (single agent) H&N, NSCLC, Lymphoma, Phase II Renal, Sarcoma, 22 (combination) Gynaecological, Pancreatic, @ the forefront of collaboration Phase III 17 (Single Agent) Breast, Lung, Liver, Prostate, Cancer Biomarker Team Phase III 13 Gynaecological, NSCLC Pharmacodynamic Biomarker Team (Combination) Drug Metabolism & Pharmacokinetic Team Cancer Biology & Cancer Evolution Team Multidisciplinary Clinical Units within RM Selective & targeted treatments National & International Clinical Trial Centres BRCA, PTEN, PI3KCA, AKT, FRα, P53, ARID A1, CRUK and ECMC collaborative projects BRAF, KRAS or NRAS, HER2, defective DNA repair genes, Mismatch repair genes Strategic alliances with Pharma Partners Acknowledgements: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support is also provided by the Experimental Cancer Medicine Centre (programme grant to the ICR) and the National Institute for Health Research Biomedical Research Centre (jointly awarded to The Royal Marsden NHS Foundation Trust and the ICR). Looking to the future: the next 10 years Acknowledgements: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support is also provided by the Experimental Cancer Medicine Centre (programme grant to the ICR) and the National Institute for Health Research Biomedical Research Centre (jointly awarded to The Royal Marsden NHS Foundation Trust and the ICR).
Load more

Recommended publications
  • A N N U Al R Ep Ort an D Accou N Ts 2 019/2 0
    Annual Report and Accounts 2013/14 The Royal Marsden NHS Foundation Trust Annual 2019/20 Report and Accounts The Royal Marsden NHS Foundation Trust Annual Report and Accounts 2019/20 Presented to Parliament pursuant to Schedule 7, paragraph 25 (4) (a) of the National Health Service Act 2006 Annual Report and Accounts 2019/20 C The Royal Marsden NHS Foundation Trust At The Royal Marsden, we deal with cancer every day, so we understand how valuable life is. And when people entrust their lives to us, they have the right to demand the very best. That’s why the pursuit of excellence lies at the heart of everything we do. Life demands excellence D The Royal Marsden NHS Foundation Trust Annual Report and Accounts 2019/20 At The Royal Marsden, we deal with Contents cancer every day, so we understand how valuable life is. And when people entrust their lives to us, they have the right to demand the very best. That’s 1. Performance report 2 why the pursuit of excellence lies at the heart of everything we do. Overview of performance 2 Summary of performance 7 Life demands excellence 2. Accountability report 15 Directors’ report 15 Remuneration report 26 Staff report 34 NHS Foundation Trust Code of Governance 44 NHS Improvement’s Single Oversight Framework 49 Statement of Accounting Officer’s responsibility 50 Annual Governance Statement 51 3. Annual Accounts for the year ended 31 March 2020 60 Foreword to the Accounts 60 Auditor’s Report 61 Four primary financial statements 70 Notes to the Accounts 74 D 1 The Royal Marsden NHS Foundation Trust 1.
    [Show full text]
  • 6 DM2019 00998 Royal Marsden.Pdf
    Page 1 Agenda Item 6 Planning Committee - Date 6 November 2019 Report of the Assistant Director of Environment, Housing and Regeneration Directorate. Ref: DM2019/00998 WARD: Belmont Time Taken: 16 weeks,1 day Site: The Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT Proposal: Erection of a six storey detached building for health purposes with clinical care, research, administration, staff restaurant and ancillary uses involving the demolition of Sycamore House and part demolition of Orchard House and cycle with car parking spaces and associated hard and soft landscaping. Applicant: Royal Marsden NHS Foundation Trust Agent: Ms Mary-Jane O'Neill Recommendation: GRANT PLANNING PERMISSION, subject to conditions and completion of the Section 106 Agreement (S106). The S106 agreement to be completed by the 22nd November 2019 or a later date as authorised in writing by the Strategic Director of Housing, Environment and Housing. Reason for Report to Committee: The application is reported to the Planning Committee ​ at the discretion of the Head of Development Management and Strategic Planning. ​ Summary of why application proposals are acceptable: ● The proposed redevelopment of this part of the London Cancer Hub would meet the aspirations of the Site Allocation LCH1 in land use terms; ● The proposed use is consistent with the established use of the surrounding area, which comprises hospital related uses; ● The Oak Cancer Centre (OCC) would increase the Royal Marsden Hospital’s capacity for research and will deliver a new and improved model
    [Show full text]
  • Royal Brompton Hospital Supplementary Planning Document Adopted May 2021 Table of Contents
    Royal Brompton Hospital Supplementary Planning Document Adopted May 2021 Table of Contents Chapter 1 - Introduction Page 5 Background and Context Vision and Objectives Planning Policy Context Relevant Local Plan Policies Existing Consents Chapter 2 - Site Analysis Page 8 Opportunities and Constraints Healthcare typologies Existing site buildings analysis Chapter 3 - Commercial/Financial Viability Page 18 Chapter 4 - Indicative Masterplan Page 20 Indicative Masterplan - Detail by site The Fulham Wing Chapter 5 - Delivery Page 28 Site A Guidance Site B Guidance Site C Guidance Site D Guidance Site wide Guidance 2 Foreword by the Lead Member for Planning, Place and Environment The coronavirus pandemic has reminded local people of the importance of world class medical facilities in our neighbourhoods. In Kensington and Chelsea - where we have put protecting lives and protecting livelihoods at the core of our mission - we are fortunate to have: • The Chelsea and Westminster Hospital, • The Royal Marsden Hospital, • and, of course, The Royal Brompton Hospital. Together, these institutions form an internationally renowned medical hub on our doorstep. However, we have recently learned of NHS plans to Councillor Johnny Thalassites merge the Royal Brompton and Guy's and St Thomas' NHS Trusts. This could see the closure of the Brompton and presents a threat that the site could be sold to the highest bidder. Kensington and Chelsea Council will actively oppose any plans to close the hospital. We believe first rate, financially viable medical facilities can be protected and enhanced on the site. We have produced this Supplementary Planning Document to demonstrate the options available to protect this brilliant centre for healthcare and research in the future.
    [Show full text]
  • Travelling to the Education and Conference Centre: Travelling by Tube
    Travelling to the Education and Conference Centre: The Royal Marsden Education and Conference Centre is situated in Stewarts Grove off of Fulham Road, London SW3 6JJ. Entrance Travelling by Tube: The nearest underground station is South Kensington which is served by the District Line (dark green), the Circle Line (bright yellow) and the Piccadilly Line (dark blue). South Kensington tube station is approximately 5 minutes’ walk away from the Education and Conference Centre. Victoria main line station is two stops away from South Kensington on either the District or Circle Lines. Paddington main line station is also accessible on the District and Circle Lines. King’s Cross St. Pancras main line station is accessible on the Piccadilly Line. Travelling by Bus: Buses 14, 211, 345 and 414 all stop outside the Royal Marsden Hospital (bus stops HP or HM: Royal Brompton Hospital / Royal Marsden Hospital). Bus 49 stops close by the hospital (bus stops HV or HT: Onslow Square), approximately 2 minutes’ walk away from the Education and Conference Centre. Education and Conferen ce Centre Education and Conferenc e Centre Buses 11, 19, 22 and 319 all stop on Kings Road (bus stops KC or KL: Chelsea Old Town Hall) which is approximately 5 minutes’ walk away from the Education and Conference Centre. Travelling by car, motorcycle or bicycle: Please note that the Royal Marsden Hospital is unable to offer car parking facilities. The hospital is in a residents' parking zone, making parking nearby difficult. There are a few metered bays but these can be quite expensive and all on-street parking in central London is prohibited.
    [Show full text]
  • Equality Report
    Equality Report January 2017 1 Contents Contents Page Introduction 4 About The Royal Marsden 4 Our commitment to equality, diversity and inclusion 4 Key achievements 6 Equality Strategy 8 Governance 8 Equality Objectives for 2016 – 2017 8 Equality Delivery System 2 (EDS2) 12 Equality Information 12 Equality Analysis 12 Care Quality Commission (CQC) 13 Workforce section . Headline data 14 . Recruitment and selection 15 . Training, education and development of staff 17 . Employee Relations 21 . Flexible working 22 . Health and Wellbeing 23 . Staff Networks 24 . Support for disabled staff and applicants 25 . Staff benefits 25 . Partnership working 25 . Leavers 26 . Staff engagement 26 2 Patient Services section 28 Headline data: The Royal Marsden Hospital patients (NHS and 28 Private Care) Headline data: The Royal Marsden Community Services patients 29 Patient engagement 30 Protected characteristics . Age 31 . Disability 34 . Gender 37 . Gender reassignment 37 . Marital/ Civil Partnership status 37 . Maternity and Pregnancy 37 . Race 38 . Religion and Belief 39 . Sexual Orientation 40 Concerns and Complaints 40 Equality priorities for action 2017/ 2018 42 Recommendations 43 3 Introduction This report highlights key findings from the 2016 equality information demonstrating initiatives used to attain our equality objectives and equality priorities in 2016. Our aim is to provide a fair and inclusive working environment and services within The Royal Marsden NHS Foundation Trust and community, which meet the personal needs of our patients and staff. About The Royal Marsden The Royal Marsden was the first hospital in the world dedicated to cancer when it opened in 1851. Its founder, William Marsden, had a vision to create a pioneering cancer hospital dedicated to the treatment and care of people with cancer and research into the underlying causes of cancer.
    [Show full text]
  • An Annual Review 2007/2008 Contents
    Building a brighter future The Royal Marsden NHS Foundation Trust An Annual Review 2007/2008 Contents 2 Chairman’s statement 3 Chief Executive’s statement 4 Innovation and technology 6 Research 8 Pioneering new services 10 Performance 14 People 18 Workforce 22 Education 24 The Royal Marsden Cancer Campaign 28 Supporters 30 Disclosure of Corporate Governance 38 Directors’ Report 40 Summary Accounts By rebuilding lives “We are committed to improving the outcomes of people with cancer everywhere, through innovation and leading edge practice. Our vision is to provide care that is truly personalised - we want to give more, better, and faster to patients. This Review describes how we are working to achieve this vision.” Cally Palmer Chief Executive By embracing change and overcoming challenges Chairman’s Statement The effective diagnosis and management the Healthcare Commission’s Annual Health Another major capital development planned I would also like to thank everyone who of patients with cancer remains one of the Check for the second consecutive year. is a new Translational Research Centre, has supported The Royal Marsden Cancer major challenges in healthcare today, with jointly funded by The National Institute Campaign in 2007/08. The generosity of The freedom of being a Foundation Trust the rising incidence of cancer globally and for Health Research, The Royal Marsden all our supporters makes a very significant has allowed us the speed and flexibility the speed of technological advance. and The Institute of Cancer Research. difference to our ability to provide world- to achieve some important developments This follows the designation of The Royal class facilities and services and to remain across both our hospital sites.
    [Show full text]
  • 70 NHS Years: a Celebration of 70 Influential Nurses and Midwives
    0 A celebration of 7 influential nurses NHS YEARS20 and midwives from 1948 to 18 In partnership with Seventy of the most influential nurses and midwives: 1948-2018 nursingstandard.com July 2018 / 3 0 7 years of nursing in the NHS Inspirational nurses and midwives who helped to shape the NHS Jane Cummings reflects on the lives of 70 remarkable As chief nursing officer for England, I am delighted figures whose contributions to nursing and to have contributed to this publication on behalf of midwifery are summarised in the following profiles, the CNOs in Northern Ireland, Scotland and Wales, and on the inspiration they provide as the profession identifying some of the most influential nurses and Jane Cummings meets today’s challenges midwives who have made a significant impact across chief nursing officer the UK and beyond. for England I would like to give special thanks to the RCNi As a nurse, when I visit front-line services and and Nursing Standard, who we have worked in meet with staff and colleagues across the country partnership with to produce this important reflection I regularly reflect on a powerful quote from the of our history over the past 70 years, and to its American author and management expert Ken sponsor Impelsys. Blanchard: ‘The key to successful leadership today is influence, not authority.’ Tireless work to shape a profession I am a firm believer that everyone in our Here you will find profiles of 70 extraordinary profession, whatever their role, wherever they work, nursing and midwifery leaders. Many of them have has the ability to influence and be influenced by the helped shape our NHS.
    [Show full text]
  • Mercure Grand Hotel, Bristol
    MERCURE GRAND HOTEL, BRISTOL CONFERENCE HANDBOOK 2018 PRINCIPAL SPONSOR GOLD SPONSORS SPONSOR UK SABR CONSORTIUM 2018 PROGRAMME THURSDAY 29 NOVEMBER 12.00 REgistration, ExhIBITIon, poSTER vIEWIng And WElComE lUnCh 13.10 Chairs’ welcome and introduction Dr Nicholas van As, Chair, UK SABR Consortium & John Lilley, Head of External Beam Radiotherapy, Leeds Cancer Centre 13.15 Opening address: New evidence in treating oligometastases; from COMET to CORE and beyond Dr David Palma, Radiation Oncologist/OICR Clinician-Scientist, London Health Sciences Centre, Canada 13.50 Motion management for SABR Marianne Aznar, Medical Physicist, The Christie NHS Foundation Trust 14.20 An update on protons – where are we? Dr Rovel Colaco, Consultant Clinical Oncologist, The Christie NHS Foundation Trust 14.40 REfREShmEnTS, ExhIBITIon And poSTER vIEWIng Chairs: Dr Anoop Haridass, Consultant Clinical Oncologist, The Clatterbridge Cancer Centre NHS Foundation Trust & Angela Baker, Radiotherapy Operational Manager, Oxford University Hospitals NHS Foundation Trust 15.10 SABR: UK implementation and current practices. Progress since 2012. Gail Distefano, Principal Clinical Scientist and NIHR Doctorate Research Fellow, Royal Surrey County Hospital and University of Surrey & Dr Satya Garikipati, Consultant Clinical Oncologist, Sheffield Teaching Hospitals NHS Trust 15.35 Results from the National SABR Spine Audit Rush Patel, Lead SABR Physicist RTTQA, Mount Vernon Cancer Centre 15.55 UK SABR Consortium – 10 years on, the past, the present and the future Dr Matthew Hatton, Consultant and Honorary Professor in Clinical Oncology, Weston Park Hospital 16.25 Profferedpapersinthespotlight 16.25 End expiration breath hold as a method of managing respiratory movement in treating abdominal structures with SABR - implementation and impact James Barber, Research and Development Radiographer, Guy’s and St.
    [Show full text]
  • AGM 2019 Meeting
    Representing and supporting Medical Oncologists in the UK 34th Annual General Meeting of the Association of Cancer Physicians Thursday 13th June 2019 Hilton Metropole, Brighton www.theacp.org.uk @acpuk Programme Apologies for Absence/New Members Changes to ACP Constitution and Rules Executive Committee Meetings and Publications Prizes Fellowships Accounts Workforce Burnout and Resilience New Consultants and Trainees Groups UK Chemotherapy Board @acpuk #ACPAGM19 Specialist Advisory Committee www.theacp.org.uk Shape of Training and Working with RCR Apologies Apologies for Absence Professor Samreen Ahmed Dr Rania Elmushraf Dr Fangfei Gao Professor Johnathan Joffe Dr Rasheid Mekki Dr Caroline Michie Dr Sam Turnbull @acpuk #ACPAGM19 www.theacp.org.uk In Memoriam In Memoriam Martin Gore Jan 2019 Jim Malpas April 2019 @acpuk #ACPAGM19 www.theacp.org.uk New Members New Members (1) Mateen Akhtar Castle Hill Hospital, Cottingham Susanna Alexander Norfolk & Norwich University Hospital Sonam Ansel Beatson West of Scotland Cancer Centre Erica Beaumont Yeovil District Hospital Rachel Bird St James Hospital Leeds Caroline Bruce NHS Lothian Lauren Cammaert NHS Grampian Florence Chamberlain St Bartholomew's Sarah Chamberlain Oxford University Hospitals NHS Foundation Trust Binu Chandrasekharapillai Janardanan Nair Cambridge University Hospitals NHS Trust Madalina Chifu Royal Cornwall Hospital Siobhan Cleary Imperial College Healthcare NHS Trust Nick Coupe Churchill Hospital Gemma Dart St James Institute of Oncology Catherine Davidson Northern Ireland
    [Show full text]
  • CV Rockall ESR Elections 2021 1
    ESR Electronic Elections 2021 Candidacy for the position of: nd 2 Vice President ESR Prof Andrea Rockall Clinical Chair of Radiology Imperial College London Hon Consultant Radiologist Imperial College Healthcare NHS Trust [email protected] Twitter:@andrea_rockall Education King's College London 1987 BSc Neuroanatomy, First Class Honours King’s College Hospital 1990 MBBS Royal College of Physicians 1993 MRCP (Internal Medicine) Royal College of Radiologists 1997 FRCR Awarded Rohan Williams (Gold) Medal Radiology Appointments 2000-2012 Senior Lecturer, Consultant Radiologist 2000 Hon Professor of Cancer Imaging 2009 Barts and The London NHS Trust and Queen Mary University London 2012-2018 Visiting Professor of Radiology, Imperial College London 2012-2015 Consultant Radiologist, Imperial College Healthcare NHS Trust 2016-2018 Consultant Radiologist, Royal Marsden Hospital NHS Foundation Trust 2018-Current Clinical Chair of Radiology, Imperial College London 2019-Current Adjunct Professor, Medical University Vienna Clinical Expertise: Genito-urinary, oncologic imaging Society and Committee Membership: Radiology ESR Chair, Statutes and Rules Subcommittee (2013-2014) Member, Membership Subcommittee (2013- 2014) Member, e-Learning Editorial Board (2014-2020) Member, Executive Council (2019-current) Chair, National Societies Committee (2019-current) Committee membership: eHealth and Informatics, Audit and Standards, Radiation Protection,including, Eurosafe Imaging, Value-based Radiology, Education, PIER RCR Steering Group, NCIN Working
    [Show full text]
  • Inpatient Guide Your Stay on Sir Reginald Wilson Ward
    Inpatient Guide Your stay on Sir Reginald Wilson Ward Royal Brompton Hospital • London CONTENTS 2 Welcome to Royal Brompton Hospital 5 Before you come to hospital 8 Travelling to hospital 10 Arriving at hospital 12 Hospital staff 14 Visitor accommodation and catering services 16 On and around the ward 17 Visitors 18 Your rights while in hospital 23 Payment of your hospital account 24 Going home after your stay - 1 - WELCOME TO ROYAL BROMPTON HOSPITAL Located on Sydney Street in Chelsea, our hospital is a national and international centre for the diagnosis and treatment of heart and lung disease. We know that coming into hospital can be a worrying time. Please be assured that we will do absolutely everything we can to make your stay as comfortable as possible. This booklet can help answer some of the questions you may have about the time before, during, and after your admission. We hope you find it useful. Please remember that our staff are always on hand to answer your questions and address any concerns – you just have to ask! We wish you a speedy recovery. - 2 - - 3 - BEFORE YOU COME TO HOSPITAL Your admission Following your consultation and/or initial referral, we will contact you via post, email or telephone to confirm the exact date and time of your admission to Royal Brompton Hospital. As a specialist centre for heart and lung disease, we often accept urgent cases, both internationally and from the United Kingdom. This means that, occasionally, urgent cases must take priority and we must cancel or delay other planned admissions.
    [Show full text]
  • The Royal Marsden Nhs Foundation Trust in Association with the Institute of Cancer Research London and Sutton Departments Of
    THE ROYAL MARSDEN NHS FOUNDATION TRUST IN ASSOCIATION WITH THE INSTITUTE OF CANCER RESEARCH LONDON AND SUTTON DEPARTMENTS OF ANAESTHESIA and INTENSIVE CARE MEDICINE JOB DESCRIPTION Senior Clinical Fellow in Medical Education and Anaesthesia/Critical Care (1 post) Whole-time fixed-term appointment for 6 months (Extendable up to 1 year subject to satisfactory review) Band 1A EWTD and New Deal compliant The Royal Marsden NHS Foundation Trust The Royal Marsden is recognised worldwide for the quality of its cancer services. The Trust’s strategic aim is to achieve excellence in cancer treatment and diagnosis, through partnership and collaboration. The prime purpose of the Trust is the provision of state of the art cancer services as well as enabling research into the development of improved methods of prevention, diagnosis and treatment of cancer. Its other main purpose is teaching and the dissemination of knowledge both nationally and internationally. In 1991 it became the first NHS hospital to be awarded the Queens Award for Technology for drug development. The hospital gained National Charter Mark Awards in 1995, 1998, 2001 and again in 2008 for the excellence of its service and in 1996 achieved the international quality standard ISO 9001 for radiotherapy in 1996 and for chemotherapy in 2003. The Royal Marsden has consistently been awarded three stars and more recently double excellent rating in the NHS performance indicators, rating it among the nations’ best in terms of clinical quality and patient care. The most recent CQC report gave an overall rating of “Good” for all services and “Outstanding” for the Chelsea site and Critical Care Services.
    [Show full text]